About Paratek Pharma
Paratek Pharma is a company based in Boston (United States) founded in 1996 was acquired by Gurnet Point Capital in June 2023.. Paratek Pharma has raised $96.48 million across 11 funding rounds from investors including Hercules Capital, HHS and Abingworth. The company has 205 employees as of December 31, 2021. Paratek Pharma has completed 2 acquisitions, including OptiNose and Transcept Pharmaceuticals. Paratek Pharma offers products and services including NUZYRA. Paratek Pharma operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Boston, United States
- Employees 205 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Paratek Pharmaceuticals, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$96.48 M (USD)
in 11 rounds
-
Latest Funding Round
-
Investors
Hercules Capital
& 18 more
-
Employee Count
205
as on Dec 31, 2021
-
Investments & Acquisitions
OptiNose
& 1 more
-
Acquired by
Gurnet Point Capital
(Jun 06, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Paratek Pharma
Paratek Pharma offers a comprehensive portfolio of products and services, including NUZYRA. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
FDA-approved tetracycline-class drug for treating bacterial infections.
Unlock access to complete
Unlock access to complete
Sales and Marketing
63 people
Leadership Team
32 people
Software Development Team
32 people
Finance and Accounting
7 people
Product Management Team
5 people
Human Resources and Administration
4 people
Legal and Compliance
4 people
Key Team
3 people
Unlock access to complete
Funding Insights of Paratek Pharma
Paratek Pharma has successfully raised a total of $96.48M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Last Round
-
First Round
First Round
(01 Nov 2002)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Grant - Paratek Pharma | Valuation |
investors |
|
| Apr, 2018 | Amount | Post-IPO - Paratek Pharma | Valuation |
investors |
|
| Jun, 2016 | Amount | Post-IPO - Paratek Pharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Paratek Pharma
Paratek Pharma has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Hercules Capital, HHS and Abingworth. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Paratek Pharma
Paratek Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include OptiNose and Transcept Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of smart devices for nasal drug delivery
|
2000 | ||||
|
Biopharmaceutical company with focus on drugs that target infectious disease, neuromuscular disease, and other difficult to treat conditions
|
1996 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Paratek Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Paratek Pharma Comparisons
Competitors of Paratek Pharma
Paratek Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| domain | founded_year | HQ Location |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| domain | founded_year | HQ Location |
Developer of antibiotics for MDR infections
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Paratek Pharma
Frequently Asked Questions about Paratek Pharma
When was Paratek Pharma founded?
Paratek Pharma was founded in 1996 and raised its 1st funding round 6 years after it was founded.
Where is Paratek Pharma located?
Paratek Pharma is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Paratek Pharma?
Michael Bigham is the current CEO of Paratek Pharma.
Is Paratek Pharma a funded company?
Paratek Pharma is a funded company, having raised a total of $96.48M across 11 funding rounds to date. The company's 1st funding round was a Post-IPO of $59.7M, raised on Nov 01, 2002.
How many employees does Paratek Pharma have?
As of Dec 31, 2021, the latest employee count at Paratek Pharma is 205.
What does Paratek Pharma do?
Paratek Pharma was founded in 1996 and is based in Boston, United States. Focus is placed on developing therapeutics to address antimicrobial resistant infections within the pharmaceutical sector. The lead product, NUZYRA (omadacycline), serves as an oral and intravenous antibiotic for treating community-acquired bacterial pneumonia and acute bacterial skin infections in adults. Seysara is also offered for managing inflammatory lesions in moderate to severe acne vulgaris.
Who are the top competitors of Paratek Pharma?
Paratek Pharma's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
What products or services does Paratek Pharma offer?
Paratek Pharma offers NUZYRA.
How many acquisitions has Paratek Pharma made?
Paratek Pharma has made 2 acquisitions, including OptiNose, and Transcept Pharmaceuticals.
Who are Paratek Pharma's investors?
Paratek Pharma has 19 investors. Key investors include Hercules Capital, HHS, Abingworth, HBM Healthcare Investments, and Lombard Odier.